Allianz Asset Management
ALLO icon

Allianz Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Allianz Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-42,400
Closed -$211K – 2178
2023
Q2 		$211K Buy
42,400
+21,600
+104% +$117K ﹤0.01% 1887
2023
Q1 		$103K Buy
+20,800
New +$133K ﹤0.01% 2067
2022
Q4 		– Sell
-20,900
Closed -$226K – 1973
2022
Q3 		$226K Sell
20,900
-24,385
-54% -$331K ﹤0.01% 1624
2022
Q2 		$516K Hold
45,285
– – ﹤0.01% 1885
2022
Q1 		$413K Sell
45,285
-9,300
-17% -$96.9K ﹤0.01% 2157
2021
Q4 		$819K Buy
54,585
+38,620
+242% +$681K ﹤0.01% 1987
2021
Q3 		$410K Hold
15,965
– – ﹤0.01% 2304
2021
Q2 		$416K Buy
+15,965
New +$455K ﹤0.01% 2129
2020
Q4 		– Sell
-17,895
Closed -$675K – 1842
2020
Q3 		$675K Sell
17,895
-1,643
-8% -$61.9K ﹤0.01% 1537
2020
Q2 		$837K Buy
+19,538
New +$707K ﹤0.01% 1876

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Allianz Asset Management's ALLO Position: Q3 2023 in Review

Allianz Asset Management sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 42,400 shares — an estimated $211K sold.

Allianz Asset Management first reported a position in ALLO in Q2 2020 and held it in 10 quarters. The position peaked at $837K in Q2 2020. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Allianz Asset Management reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Allianz Asset Management sold 42,400 Allogene Therapeutics shares in Q3 2023, an estimated $211K.
  • Allianz Asset Management first reported a position in Allogene Therapeutics in Q2 2020 and held it in 10 quarters.
  • Allianz Asset Management's Allogene Therapeutics position peaked at $837K in Q2 2020.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Allianz Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.